PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 139 filers reported holding PROTAGONIST THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 2.23 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $26,928,000 | +19.8% | 600,010 | -30.9% | 1.19% | +28.7% |
| Q1 2021 | $22,474,000 | +28.5% | 867,724 | 0.0% | 0.93% | +23.7% |
| Q4 2020 | $17,493,000 | +12.6% | 867,724 | +9.2% | 0.75% | -2.7% |
| Q3 2020 | $15,530,000 | +6.7% | 794,369 | -3.6% | 0.77% | -18.0% |
| Q2 2020 | $14,555,000 | +195.4% | 824,169 | +18.1% | 0.94% | +185.7% |
| Q1 2020 | $4,927,000 | +45.9% | 697,899 | +45.7% | 0.33% | +51.6% |
| Q4 2019 | $3,377,000 | -41.3% | 479,074 | 0.0% | 0.22% | -78.0% |
| Q3 2019 | $5,754,000 | +1891.0% | 479,074 | +1904.4% | 0.99% | +2365.0% |
| Q2 2019 | $289,000 | – | 23,901 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $19,373,000 | 4.95% |
| Bain Capital Life Sciences Investors, LLC | 2,260,572 | $17,881,000 | 2.10% |
| Finepoint Capital LP | 735,126 | $5,815,000 | 2.01% |
| Altium Capital Management LP | 365,100 | $2,888,000 | 1.16% |
| RTW INVESTMENTS, LP | 4,794,499 | $37,924,000 | 0.98% |
| Amitell Capital Pte Ltd | 50,129 | $397,000 | 0.90% |
| COWEN AND COMPANY, LLC | 1,065,724 | $8,430,000 | 0.81% |
| Tri Locum Partners LP | 155,000 | $1,226,000 | 0.50% |
| BVF INC/IL | 1,106,838 | $8,755,000 | 0.42% |
| HighVista Strategies LLC | 46,459 | $367,000 | 0.22% |